用头孢地尔治疗耐碳青霉烯类肺炎克雷伯菌医院获得性脑室外引流相关性脑膜炎：简要报告。
Treatment with cefiderocol in KPC nosocomial external ventricular drainage meningitis: A brief report.
作者信息
Colombo Francesco, Waheed Ali, Panese Sandro, Scarparo Claudio, Solinas Maria, Parisi Saverio Giuseppe, Geremia Nicholas
机构信息
Department of Molecular Medicine, University of Padova, Padua, Italy.
Unit of Infectious Diseases, Department of Clinical Medicine, Ospedale dell'Angelo, Venice, Italy.
出版信息
Infez Med. 2022 Sep 1;30(3):454-458. doi: 10.53854/liim-3003-15. eCollection 2022.
Abstract
We report the case of successful use of cefiderocol (FDC) in a (CPKP) post-surgical meningitis in a 44-year-old man treated with antimicrobial therapy and external ventricular drainage (EVD). The patient was known for being colonised by CPKP; for this reason, therapy with ceftazidime/avibactam (CZA) plus fosfomycin and linezolid was started. After an initial response a CZA resistant CPKP strain was isolated from CSF culture, so the antibiotic therapy was modified to FDC with trimethoprim/sulfamethoxazole for 14 days, and EVD was replaced. A complete recovery was obtained. This is the first case report describing FDC administration in CPKP meningitis.
摘要
我们报告了一例成功使用头孢地尔（FDC）治疗一名44岁男性术后脑膜炎（由肺炎克雷伯菌产碳青霉烯酶菌株引起，CPKP）的病例，该患者接受了抗菌治疗和脑室外引流（EVD）。该患者已知被CPKP定植；因此，开始使用头孢他啶/阿维巴坦（CZA）联合磷霉素和利奈唑胺进行治疗。在初始反应后，从脑脊液培养物中分离出一株对CZA耐药的CPKP菌株，因此将抗生素治疗改为使用FDC联合甲氧苄啶/磺胺甲恶唑治疗14天，并更换了EVD。患者完全康复。这是第一例描述在CPKP脑膜炎中使用FDC的病例报告。
相似文献
1
Treatment with cefiderocol in KPC nosocomial external ventricular drainage meningitis: A brief report.用头孢地尔治疗耐碳青霉烯类肺炎克雷伯菌医院获得性脑室外引流相关性脑膜炎：简要报告。
Infez Med. 2022 Sep 1;30(3):454-458. doi: 10.53854/liim-3003-15. eCollection 2022.
2
Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.碳青霉烯类耐药肠杆菌科（CRE）对头孢地尔和头孢他啶-阿维巴坦的交叉耐药性及其接种物效应。
Clin Microbiol Infect. 2021 Aug;27(8):1172.e7-1172.e10. doi: 10.1016/j.cmi.2021.04.016. Epub 2021 Apr 26.
3
Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants.产 KPC 变体的临床分离株对头孢他啶-阿维巴坦和头孢地尔的共同耐药性。
Eur J Clin Microbiol Infect Dis. 2022 Apr;41(4):677-680. doi: 10.1007/s10096-021-04397-x. Epub 2022 Jan 28.
4
In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.头孢地尔在体外对头孢他啶-阿维巴坦敏感和耐药的产 KPC 肠杆菌科的活性：交叉耐药性和协同作用。
Eur J Clin Microbiol Infect Dis. 2022 Jan;41(1):63-70. doi: 10.1007/s10096-021-04341-z. Epub 2021 Aug 31.
5
First Description of Ceftazidime/Avibactam Resistance in a ST13 KPC-70-Producing Strain from Portugal.葡萄牙一株产KPC-70的ST13菌株中头孢他啶/阿维巴坦耐药性的首次描述。
Antibiotics (Basel). 2022 Jan 27;11(2):167. doi: 10.3390/antibiotics11020167.
6
Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.在 COVID-19 时代，产碳青霉烯酶肠杆菌科细菌中多碳青霉烯酶的产生情况以及包含头孢地尔、头孢他啶-阿维巴坦、美罗培南-沃巴坦和氨曲南的联合用药的体外活性。
Eur J Clin Microbiol Infect Dis. 2022 Apr;41(4):573-580. doi: 10.1007/s10096-022-04408-5. Epub 2022 Jan 21.
7
Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China.药代动力学/药效学模型评估头孢他啶/阿维巴坦不同给药方案治疗产碳青霉烯酶肺炎克雷伯菌（KPC）肺炎克雷伯菌引起的肺炎的疗效：中国北方多中心研究。
J Glob Antimicrob Resist. 2021 Dec;27:67-71. doi: 10.1016/j.jgar.2021.07.020. Epub 2021 Aug 21.
8
KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae.产碳青霉烯酶的肺炎克雷伯菌对头孢他啶-阿维巴坦的耐药性及对其的交叉耐药性。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0089021. doi: 10.1128/AAC.00890-21.
9
Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing .头孢他啶-阿维巴坦单药及与厄他培南、磷霉素和替加环素联合治疗产碳青霉烯酶肠杆菌科细菌的活性
Microb Drug Resist. 2019 Nov;25(9):1357-1364. doi: 10.1089/mdr.2018.0234. Epub 2019 Jul 11.
10
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
引用本文的文献
1
Managing Multidrug-Resistant spp.: current evidence and knowledge gaps.管理多重耐药菌：当前证据与知识空白
Infez Med. 2025 Sep 1;33(3):261-267. doi: 10.53854/liim-3303-2. eCollection 2025.
2
Fluoroquinolones and Biofilm: A Narrative Review.氟喹诺酮类药物与生物膜：一篇叙述性综述。
Pharmaceuticals (Basel). 2024 Dec 11;17(12):1673. doi: 10.3390/ph17121673.
3
Role of Cefiderocol in Multidrug-Resistant Gram-Negative Central Nervous System Infections: Real Life Experience and State-of-the-Art.头孢地尔在多重耐药革兰阴性菌中枢神经系统感染中的作用：真实病例经验与最新进展
Antibiotics (Basel). 2024 May 16;13(5):453. doi: 10.3390/antibiotics13050453.
4
New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections.用于治疗医院获得性中枢神经系统感染的新型抗生素
Antibiotics (Basel). 2024 Jan 7;13(1):58. doi: 10.3390/antibiotics13010058.
5
Resistance in : A Narrative Review of Antibiogram Interpretation and Emerging Treatments.《耐药性：抗菌谱解读与新兴治疗方法的叙述性综述》
Antibiotics (Basel). 2023 Nov 12;12(11):1621. doi: 10.3390/antibiotics12111621.
6
Treatment of Ventriculitis and Meningitis After Neurosurgery Caused by Carbapenem-Resistant (CRE): A Challenging Topic.耐碳青霉烯类肠杆菌科细菌（CRE）所致神经外科术后脑室炎和脑膜炎的治疗：一个具有挑战性的课题。
Infect Drug Resist. 2023 Jun 15;16:3807-3818. doi: 10.2147/IDR.S416948. eCollection 2023.
7
Dark Brown Urine in a Patient Treated With Cefiderocol.接受头孢地尔治疗的患者出现深棕色尿液。
Infez Med. 2023 Jun 1;31(2):265-267. doi: 10.53854/liim-3102-16. eCollection 2023.
8
Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales.头孢地尔，一种铁载体头孢菌素，作为耐碳青霉烯类肠杆菌科细菌所致感染的一种治疗选择。
Infect Dis Ther. 2023 Mar;12(3):777-806. doi: 10.1007/s40121-023-00773-6. Epub 2023 Feb 25.
本文引用的文献
1
Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing.革兰氏阴性多重耐药杆菌对头孢他啶/阿维巴坦、美罗培南/瓦博巴坦和亚胺培南/瑞来巴坦的耐药性：分子机制与药敏试验
Antibiotics (Basel). 2022 May 6;11(5):628. doi: 10.3390/antibiotics11050628.
2
Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.头孢地尔治疗多重耐药革兰阴性菌：对现有证据的系统评价
Front Pharmacol. 2022 Apr 12;13:896971. doi: 10.3389/fphar.2022.896971. eCollection 2022.
3
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant (DTR-P) infections.头孢地尔同情用药治疗难治性耐药（DTR-P）感染的真实生活经验。
JAC Antimicrob Resist. 2021 Dec 11;3(4):dlab188. doi: 10.1093/jacamr/dlab188. eCollection 2021 Dec.
4
Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol.头孢地尔的临床药代动力学与药效学
Clin Pharmacokinet. 2021 Dec;60(12):1495-1508. doi: 10.1007/s40262-021-01063-5. Epub 2021 Aug 22.
5
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia.肺部药物动力学：机械通气肺炎患者头孢地尔的体内过程。
J Antimicrob Chemother. 2021 Oct 11;76(11):2902-2905. doi: 10.1093/jac/dkab280.
6
7
Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology.耐碳青霉烯类肠杆菌科细菌：新型抗菌药物时代及酶学不断演变背景下的治疗考量
Curr Infect Dis Rep. 2020 Feb 7;22(3):6. doi: 10.1007/s11908-020-0716-3.
8
Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin.头孢地尔的药代动力学和药效学特征，一种新型的铁载体头孢菌素。
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S552-S558. doi: 10.1093/cid/ciz828.
9
10
Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.头孢地尔罗（S-649266），一种新型的铁载体头孢菌素，对铜绿假单胞菌和其他革兰氏阴性病原体具有强大的活性，包括多药耐药菌：构效关系。
Eur J Med Chem. 2018 Jul 15;155:847-868. doi: 10.1016/j.ejmech.2018.06.014. Epub 2018 Jun 8.
Zotero 插件